Laser capture microdissection analysis reveals frequent allelic losses in papillary urothelial neoplasm of low malignant potential of the urinary bladder

Liang Cheng, Gregory T. MacLennan, Shaobo Zhang, Mingsheng Wang, Chong Xian Pan, Michael O. Koch

Research output: Contribution to journalArticle

62 Scopus citations

Abstract

BACKGROUND. In the 1999 World Health Organization classification system, papillary tumors of the urinary bladder were classified as papilloma, papillary urothelial neoplasm of low malignant potential (PUNLMP), and as Grade 1, Grade 2, and Grade 3 urothelial carcinoma. The biologic potential of PUNLMP of the urinary bladder is controversial. To the authors' knowledge, information regarding the genetic changes of PUNLMP tumors of the bladder is limited. METHODS. The authors examined loss of heterogygosity (LOH) at 5 polymorphic microsatellite markers on chromosome 9q32-33 (D9S177), 9p22 (IFNA), 17p13.1 (TP53), 12q14-24 (D12S1051), and 3p25-26 (D3S3050) from 26 patients who were diagnosed with PUNLMP tumors of the urinary bladder. Tumors were microdissected from sections prepared from formalin-fixed, paraffin-processed tissue specimens using laser capture microdissection. RESULTS. LOH was found in 21 of 26 (81%) patients with PUNLMP. The rate of LOH was 41% with D9S177, 32% with IFNA, 29% with TP53, 26% with D12S1051, and 44% with D3S3050. Allelic loss of multiple chromosome loci was often present in patients with PUNLMP tumors. CONCLUSIONS. Genetic changes that commonly occur in advanced bladder carcinoma (≥ pT2) are frequently found in PUNLMP of the urinary bladder.

Original languageEnglish (US)
Pages (from-to)183-188
Number of pages6
JournalCancer
Volume101
Issue number1
DOIs
StatePublished - Jul 1 2004

    Fingerprint

Keywords

  • Grading
  • Laser capture microdissection
  • Loss of heterozygosity
  • Neoplasms
  • Papillary urothelial neoplasm of low malignant potential
  • Urinary bladder
  • Urothelial (transitional cell) carcinoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this